anyway, to be more explicit -
A drug company that releases a product after a sub-standard vetting procedure is at a heightened risk of the product either failing or causing some (hopefully) unintended harm.
If the public demands that the drug company extraordinarily rush-release a product, the public should not thereafter penalize the company for the potential extraordinary harm resulting from the public's extraordinary demand.
That said, people may still innocently be injured from the rush-release, so some measure of compensation is still appropriate.
In that case, the public itself, through the agency of the government, should provide the relief to the injured person, in order to enable the rush-delivery of the product to the remainder of the public.
In case not everybody here is familiar with the concept of "indemnity", it does not mean "no recovery":
Quote:
Indemnity is a contractual obligation of one party to compensate the loss incurred to the other party due to the acts of the indemnitor or any other party.
So if Pfizer releases a vaccine, and 90% of the people are benefited but 10% do not, the entire public covers the loss of the 10% (aka "risk pooling").